Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
M. Oliveira, C. Falato, J.M. Cejalvo, M. Margelí Vila, P. Tolosa, F.J. Salvador-Bofill, J. Cruz, M. Arumi, A.M. Luna, J.A. Guerra, M. Vidal, O. Martínez-Sáez, L. Paré, B. González-Farré, E. Sanfeliu, E. Ciruelos, M. Espinosa-Bravo, S. Pernas, Y. Izarzugaza, S. Esker, P.-D. Fan, P. Parul, A. Santhanagopal, D. Sellami, G. Villacampa, J.M. Ferrero-Cafiero., T. Pascual, A. Prat
Manuscrito
Annals of Oncology
2023
TOT-HER3
